Protocol Ledger

NCT05048849 · Phase II · COMPLETED

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study

Interventional Phase II clinical trial protocol NCT05048849 sponsored by Medigen Vaccine Biologics in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-19 Enrollment: 274 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05048849
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)274 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05048849
Protocol FieldVerified Registry Value
NCT IdentifierNCT05048849
Consolidated Lead SponsorMedigen Vaccine Biologics
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment274 participants (ACTUAL)
Registered Start Date2021-07-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI